Enrico De Astis, Marino Clavio, Anna Maria Raiola, Anna Ghiso, Fabio Guolo, Paola Minetto, Federica Galaverna, Maurizio Miglino, Carmen Di Grazia, Filippo Ballerini, Carlo Marani, Giordana Pastori, Laura Mitscheunig, Fabio Cruciani, Davide Lovera, Riccardo Varaldo, Chiara Ghiggi, Roberto Massimo Lemoli, Andrea Bacigalupo, Marco Gobbi
Therapeutic options for patients with relapsed or refractory acute leukemia are still undefined and often unsatisfactory. We report the outcome of 79 patients with relapsed-refractory acute leukemia treated with fludarabine, cytarabine, and liposomal daunorubicin (FLAD regimen) followed by hematopoietic stem cell transplantation (HSCT), when clinically indicated, between May 2000 and January 2013. Forty-one patients had acute myeloid leukemia (AML), and 38 had acute lymphoblastic leukemia (ALL). Two patients with myeloid blast crises of CML and three with lymphoid blast crises were included in the AML and ALL subgroups, respectively...
December 2014: Annals of Hematology